Ascletis advances once-monthly ASC36 and ASC36_35 obesity injections into FDA review
Discover why Ascletis’ monthly ASC36 and ASC36_35 obesity drugs matter, and which clinical risks could determine their future.
Pharma & Biotech
Pharma & Biotech
Evidation GLP-1 study reveals major growth runway but exposes widening access gaps
Discover how Evidation’s 165,000-person study reveals GLP-1 growth potential, access gaps and persistence risks shaping obesity care. Read more.
Pharma & Biotech
Corcept’s Korlym data put hypercortisolism back in focus for cardiometabolic disease
Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.
Pharma & Biotech
Phoenix and Raven launch direct-to-patient generic semaglutide after Health Canada approval
Generic semaglutide is cheaper, but access is now the real battleground. Phoenix and Raven are testing Canada’s GLP-1 telehealth future.
Pharma & Biotech
Why TIXiMED’s TIX100 data highlights a growing therapeutic gap after GLP-1 weight-loss treatment
TIXiMED reports preclinical data showing oral TIX100 may prevent weight regain after GLP-1 therapy. Discover what this could mean for obesity treatment.
Pharma & Biotech
What Veru Inc.’s Phase 2b PLATEAU trial signals about the evolution of combination obesity drugs
Veru Inc. launches Phase 2b PLATEAU trial combining enobosarm with semaglutide for obesity. Discover what it means for next-generation weight-loss drugs.
Pharma & Biotech
Can Sciwind Biosciences’ ecnoglutide challenge conventional GLP-1 drugs in the expanding obesity market?
China approves Sciwind Biosciences’ ecnoglutide for weight management. Discover what the biased GLP-1 mechanism could change in the obesity drug race.
Pharma & Biotech
Can Novo Nordisk’s semaglutide 7.2 mg set a new standard in obesity treatment?
Novo Nordisk's semaglutide 7.2 mg achieves 20.7% weight loss. Find out what this EU regulatory step means for obesity treatment and patient outcomes in 2026.